Discontinued — last reported Q2 '25
Current Assets
Finished goods
Vertex Pharmaceuticals Finished goods increased by 17.6% to $252.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 33.6%, from $188.60M to $252.00M. Over 4 years (FY 2020 to FY 2024), Finished goods shows an upward trend with a 26.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2017
Last reportedQ2 2025
Parent metricInventories
How to read this metric
An increase relative to sales may signal slowing demand or overproduction; a decrease may indicate strong sales or supply chain constraints.
Detailed definition
This represents the value of inventory that has completed the manufacturing process and is ready for sale to customers....
Peer comparison
Standard inventory metric for all manufacturing and retail companies.
Metric ID:
inv_finished_goodsHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $91.23M | $94.82M | $86.70M | $90.90M | $100.70M | $126.70M | $161.80M | $135.90M | $132.80M | $112.90M | $135.00M | $115.60M | $144.90M | $188.60M | $184.60M | $208.00M | $214.30M | $252.00M |
| QoQ Change | — | +3.9% | -8.6% | +4.8% | +10.8% | +25.8% | +27.7% | -16.0% | -2.3% | -15.0% | +19.6% | -14.4% | +25.3% | +30.2% | -2.1% | +12.7% | +3.0% | +17.6% |
| YoY Change | — | — | — | — | +10.4% | +33.6% | +86.6% | +49.5% | +31.9% | -10.9% | -16.6% | -14.9% | +9.1% | +67.1% | +36.7% | +79.9% | +47.9% | +33.6% |
| % of Inventories | 28.4% | 28.4% | 24.6% | 26.8% | 27.4% | 32.6% | 35.1% | 25.4% | 22.0% | 16.4% | 18.3% | 14.2% | 15.8% | 17.5% | 15.3% | 15.3% | 14.3% | 15.5% |
| Share Change | — | +0.1pp | -3.9pp | +2.3pp | +0.6pp | +5.3pp | +2.5pp | -9.7pp | -3.4pp | -5.6pp | +1.9pp | -4.1pp | +1.6pp | +1.6pp | -2.2pp | -0.0pp | -1.0pp | +1.2pp |
Range$86.70M – $252.00M
CAGR+27.0%
Avg YoY Growth+31.7%
Median YoY Growth+33.6%
Current Streak3 quarters growth
Finished goods at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's finished goods?
- Vertex Pharmaceuticals (VRTX) reported finished goods of $252.00M in Q3 2025.
- How has Vertex Pharmaceuticals's finished goods changed year-over-year?
- Vertex Pharmaceuticals's finished goods increased by 33.6% year-over-year, from $188.60M to $252.00M.
- What is the long-term trend for Vertex Pharmaceuticals's finished goods?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's finished goods has grown at a 26.0% compound annual growth rate (CAGR), from $73.22M to $184.60M.
- What does finished goods mean?
- The value of completed products ready for sale.